HUMAN IPSC-DERIVED MACROPHAGE

Organization Name

The Regents of the University of California

Inventor(s)

HUMAN IPSC-DERIVED MACROPHAGE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18579425 titled 'HUMAN IPSC-DERIVED MACROPHAGE

Simplified Explanation: The patent application discusses the creation of human iPSC-derived macrophages, including those expressing chimeric antigenic receptors (CARs), for the treatment of cancer and other conditions.

Human iPSC-derived macrophages are manufactured with CARs like Bai1, MegF10, or MerTK, known as iPSC-derived CAR-expressing macrophages (iPSC-CARMAs).
These iPSC-CARMAs are used in combination with specific antibodies for cancer, such as anti-CD47 or anti-EGFR antibodies, to reduce tumor burden and improve patient survival.

Potential Applications: 1. Cancer treatment 2. Immunotherapy 3. Treatment of other conditions involving macrophage activity

Problems Solved: 1. Enhancing phagocytic activity against cancer cells 2. Reducing tumor burden 3. Improving patient survival rates

Benefits: 1. Targeted treatment with CAR-expressing macrophages 2. Enhanced immune response against cancer 3. Potential for personalized medicine approaches

Commercial Applications: The technology could be utilized in the development of novel cancer therapies and immunotherapies, potentially leading to new treatment options in the pharmaceutical market.

Questions about iPSC-derived CAR-expressing macrophages: 1. How do iPSC-derived CAR-expressing macrophages differ from traditional macrophages in cancer treatment? 2. What are the potential challenges in the widespread adoption of iPSC-derived CAR-expressing macrophages in clinical settings?

Original Abstract Submitted

Human iPSC-derived macrophages, methods for the manufacture thereof, and methods of treatment of cancer and other conditions therewith. Human iPSC-derived macrophages further comprise a chimeric antigenic receptor (CAR) expressed thereon, such as Bai1, MegF10 or MerTK, referred to as iPSC-derived CAR-expressing macrophages (iPSC-CARMAs). The methods of treatment provide further co-administering to the subject an effective amount of iPSC-CARMAs and an antibody specific for the cancer, such as anti-CD47 or anti-EGFR antibody. The iPSC-derived macrophages promote phagocytic activity, reduce tumor burden, and improve subject survival.